EUROPE ANTI FUNGAL MARKET FORECAST 2017-2025
KEY FINDINGS
The Europe antifungal agents market is expected to increaseat a CAGR of 7.10% in the forecasted period of 2017-2025. The market was valued to be $1899 million in 2016 and is expected to surge to $3508 million by 2025. Poor hygiene, developing new drug resistance and initiatives taken by the government in healthcare policies and programs are some of the factors helping the market to move ahead.
MARKET INSIGHTS
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines, and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. Alternate treatment options and regulatory conditions are the restraints faced by the anti-fungal market.
COMPETITIVE INSIGHTS
The major market players in the antifungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, AstellasPharmaInc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson&Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.
The Europe antifungal agents market is expected to increaseat a CAGR of 7.10% in the forecasted period of 2017-2025. The market was valued to be $1899 million in 2016 and is expected to surge to $3508 million by 2025. Poor hygiene, developing new drug resistance and initiatives taken by the government in healthcare policies and programs are some of the factors helping the market to move ahead.
MARKET INSIGHTS
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines, and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. Alternate treatment options and regulatory conditions are the restraints faced by the anti-fungal market.
COMPETITIVE INSIGHTS
The major market players in the antifungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, AstellasPharmaInc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson&Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUG
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE ANTI FUNGAL AGENTS MARKET
7.1.1. UK ANTI FUNGAL AGENTS MARKET
7.1.2. FRANCE ANTI FUNGAL AGENTS MARKET
7.1.3. GERMANY ANTI FUNGAL AGENTS MARKET
7.1.4. SPAIN ANTI FUNGAL AGENTS MARKET
7.1.5. ITALYANTI FUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. 3 BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. GILEAD
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. GLAXOSMITHKLINE
9.8.1. OVERVIEW
9.8.2. PRODUCT PROTOFLIO PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. JOHNSON & JOHNSON
9.9.1. OVERVIEW
9.9.2. PRODUCTS
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. KRAMER LABORATORIES
9.10.1. OVERVIEW
9.10.2. PRODUCTS
9.10.3. SCOT ANALYSIS
9.11. MERCK & CO.
9.11.1. OVERVIEW
9.11.2. PRODUCT PROTOFLIO PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC MOVES
9.12. NOVARTIS
9.12.1. OVERVIEW
9.12.2. PRODUCTS
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. PFIZER
9.13.1. OVERVIEW
9.13.2. PRODUCTS
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SANOFI-AVENTIS
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. VERTEX PHARMACEUTICALS
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 2 EUROPE ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
TABLE 3 DRUG USES OF TRIAZOLES
TABLE 4 EUROPE AZOLES MARKET 2017-2025 ($ MILLION)
TABLE 5 EUROPE POLYENES MARKET 2017-2025 ($ MILLION)
TABLE 6 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 7 EUROPE ALLYLAMINES MARKET 2017-2025 ($ MILLION)
TABLE 8 EUROPE ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
TABLE 9 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 10 EUROPE DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 12 EUROPE CANDIDIASIS MARKET 2017-2025 ($ MILLION)
TABLE 13 EUROPE OTHERS MARKET 2017-2025 ($ MILLION)
TABLE 14 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 15 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 16 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 17 ANTIFUNGAL PASTES AND its EFFECT
TABLE 18 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND its EFFECTS
TABLE 19 EUROPE ANTI-FUNGAL AGENT MARKET 2017-2025 ($ MILLION)
TABLE 20 FINAL CONSUMPTION OF MEDICAL GOODS AND SERVICES BY HOUSEHOLD
TABLE 21 TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2015
FIGURES LIST
FIGURE 1 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 2 EUROPE ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 3 EUROPE AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 4 EUROPE POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 5 EUROPE ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 6 EUROPE OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 7 EUROPE ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 8 EUROPE DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 9 EUROPE CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 EUROPE OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 11 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 12 EUROPE TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 13 EUROPE ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 14 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 15 PHARMACEUTICAL SALES IN DIFFERENT COUNTRIES IN EUROPE 2014 ($ MILLION)
FIGURE 16 HEALTHCARE EXPENDITURE IN UK 2010-2015 (£ BILLION)
FIGURE 17 U.K. ANTIFUNGAL AGENTS MARKET 2017-2025 ($MILLION)
FIGURE 18 INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2015 (%)
FIGURE 19 FRANCE ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 20 GERMANY ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 21 SPAIN ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 22 ITALY ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 23 ROE ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUG
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE ANTI FUNGAL AGENTS MARKET
7.1.1. UK ANTI FUNGAL AGENTS MARKET
7.1.2. FRANCE ANTI FUNGAL AGENTS MARKET
7.1.3. GERMANY ANTI FUNGAL AGENTS MARKET
7.1.4. SPAIN ANTI FUNGAL AGENTS MARKET
7.1.5. ITALYANTI FUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. 3 BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. GILEAD
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. GLAXOSMITHKLINE
9.8.1. OVERVIEW
9.8.2. PRODUCT PROTOFLIO PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. JOHNSON & JOHNSON
9.9.1. OVERVIEW
9.9.2. PRODUCTS
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. KRAMER LABORATORIES
9.10.1. OVERVIEW
9.10.2. PRODUCTS
9.10.3. SCOT ANALYSIS
9.11. MERCK & CO.
9.11.1. OVERVIEW
9.11.2. PRODUCT PROTOFLIO PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC MOVES
9.12. NOVARTIS
9.12.1. OVERVIEW
9.12.2. PRODUCTS
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. PFIZER
9.13.1. OVERVIEW
9.13.2. PRODUCTS
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SANOFI-AVENTIS
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. VERTEX PHARMACEUTICALS
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 2 EUROPE ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
TABLE 3 DRUG USES OF TRIAZOLES
TABLE 4 EUROPE AZOLES MARKET 2017-2025 ($ MILLION)
TABLE 5 EUROPE POLYENES MARKET 2017-2025 ($ MILLION)
TABLE 6 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 7 EUROPE ALLYLAMINES MARKET 2017-2025 ($ MILLION)
TABLE 8 EUROPE ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
TABLE 9 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 10 EUROPE DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 12 EUROPE CANDIDIASIS MARKET 2017-2025 ($ MILLION)
TABLE 13 EUROPE OTHERS MARKET 2017-2025 ($ MILLION)
TABLE 14 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 15 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 16 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 17 ANTIFUNGAL PASTES AND its EFFECT
TABLE 18 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND its EFFECTS
TABLE 19 EUROPE ANTI-FUNGAL AGENT MARKET 2017-2025 ($ MILLION)
TABLE 20 FINAL CONSUMPTION OF MEDICAL GOODS AND SERVICES BY HOUSEHOLD
TABLE 21 TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2015
FIGURES LIST
FIGURE 1 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 2 EUROPE ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 3 EUROPE AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 4 EUROPE POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 5 EUROPE ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 6 EUROPE OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 7 EUROPE ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 8 EUROPE DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 9 EUROPE CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 EUROPE OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 11 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 12 EUROPE TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 13 EUROPE ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 14 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 15 PHARMACEUTICAL SALES IN DIFFERENT COUNTRIES IN EUROPE 2014 ($ MILLION)
FIGURE 16 HEALTHCARE EXPENDITURE IN UK 2010-2015 (£ BILLION)
FIGURE 17 U.K. ANTIFUNGAL AGENTS MARKET 2017-2025 ($MILLION)
FIGURE 18 INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2015 (%)
FIGURE 19 FRANCE ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 20 GERMANY ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 21 SPAIN ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 22 ITALY ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 23 ROE ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
